Key Highlights
- Amgen has committed an additional $300 million to expand its Juncos, Puerto Rico biologics manufacturing site.
- The Puerto Rico facility supplies biologic medicines to over 60 nations worldwide and will undergo capacity enhancements.
- This investment builds upon more than $650 million previously earmarked for Puerto Rico operations within the last twelve months.
- Amgen’s aggregate U.S. manufacturing investments in recent months surpass $3.65 billion, spanning facilities in Puerto Rico, Ohio, California, and North Carolina.
- The announcement arrives amid heightened scrutiny from the Trump administration, which has threatened steep tariffs on pharmaceutical imports.
Amgen (AMGN) shares declined 1.54% during Monday’s trading session following the biotechnology company’s announcement of a $300 million capital commitment to enhance its biologics production operations in Juncos, Puerto Rico.
The capital deployment targets increased manufacturing throughput and the implementation of cutting-edge production technologies at the facility, which has served as a cornerstone of Amgen’s operations since its establishment in 1992.
Currently, the Juncos manufacturing complex ships biologic pharmaceutical products to more than 60 international markets. The financial commitment will bolster existing employment at the site while generating several hundred temporary construction positions.
Chief Executive Officer Robert Bradway characterized the expansion as evidence of Amgen’s “unwavering dedication to American manufacturing capabilities” and emphasized its role in securing domestic pharmaceutical supply networks and ensuring uninterrupted patient medication access.
Puerto Rico’s Governor, Jenniffer González Colón, praised the development, asserting that the investment validates the effectiveness of policies designed to strengthen the island’s biopharmaceutical manufacturing ecosystem.
The $300 million injection supplements a previously announced $650 million allocated to Puerto Rico facilities over the preceding year, which was projected to generate approximately 750 employment opportunities.
Nationwide Manufacturing Expansion Strategy
This newest financial pledge represents one component of a comprehensive domestic manufacturing initiative. Throughout the past year, Amgen has unveiled $900 million in capital expenditures for Ohio operations, $600 million designated for a California-based science and innovation hub, and upwards of $1.5 billion committed to North Carolina facilities.
Including the latest Puerto Rico announcement, Amgen’s recent domestic manufacturing pledges exceed $3.65 billion in total value.
Following the implementation of the Tax Cuts and Jobs Act in 2017, Amgen reports having allocated more than $40 billion toward manufacturing infrastructure and research and development initiatives.
Navigating Trade Policy Headwinds
The investment unfolds against a backdrop of intensifying regulatory pressure on international pharmaceutical manufacturers from the current administration.
In April, President Trump executed an executive directive implementing 100% import tariffs on branded pharmaceutical products entering the United States, contingent upon manufacturers either accepting federal drug pricing agreements or establishing domestic production facilities.
Amgen’s broadened domestic manufacturing infrastructure strategically positions the organization to address these regulatory challenges, though company leadership characterized the Puerto Rico enhancement as a component of a comprehensive, long-term supply chain optimization initiative.
Puerto Rico, as a U.S. territory, has functioned as a pharmaceutical manufacturing stronghold for more than six decades and hosts numerous major pharmaceutical corporation facilities.
The Juncos location has operated within Amgen’s global manufacturing network since 1992 and serves a critical function in the company’s worldwide biologics distribution system.
Amgen has not disclosed a definitive completion timeline for the Puerto Rico expansion project.
